Skip to main content
NCBI home page
ACS Omega logoLink to ACS Omega
. 2022 Apr 13;7(16):13667–13675. doi: 10.1021/acsomega.1c07231

Identification of a Trm732 Motif Required for 2′-O-methylation of the tRNA Anticodon Loop by Trm7

Holly M Funk †, Daisy J DiVita †, Hannah E Sizemore †, Kendal Wehrle †, Catherine L W Miller ‡, Morgan E Fraley †, Alex K Mullins †, Adrian R Guy †, Eric M Phizicky ‡, Michael P Guy †,‡,*
PMCID: PMC9088939  PMID: 35559166

Abstract

graphic file with name ao1c07231_0006.jpg

Posttranscriptional tRNA modifications are essential for proper gene expression, and defects in the enzymes that perform tRNA modifications are associated with numerous human disorders. Throughout eukaryotes, 2′-O-methylation of residues 32 and 34 of the anticodon loop of tRNA is important for proper translation, and in humans, a lack of these modifications results in non-syndromic X-linked intellectual disability. In yeast, the methyltransferase Trm7 forms a complex with Trm732 to 2′-O-methylate tRNA residue 32 and with Trm734 to 2′-O-methylate tRNA residue 34. Trm732 and Trm734 are required for the methylation activity of Trm7, but the role of these auxiliary proteins is not clear. Additionally, Trm732 and Trm734 homologs are implicated in biological processes not directly related to translation, suggesting that these proteins may have additional cellular functions. To identify critical amino acids in Trm732, we generated variants and tested their ability to function in yeast cells. We identified a conserved RRSAGLP motif in the conserved DUF2428 domain of Trm732 that is required for tRNA modification activity by both yeast Trm732 and its human homolog, THADA. The identification of Trm732 variants that lack tRNA modification activity will help to determine if other biological functions ascribed to Trm732 and THADA are directly due to tRNA modification or to secondary effects due to other functions of these proteins.

Introduction

tRNA from all organisms is extensively modified.1 These modifications are required for proper tRNA function and translation and therefore play an important role in gene expression. In the yeast Saccharomyces cerevisiae, a lack of cytoplasmic tRNA modifications causes varied phenotypes including slow growth, temperature sensitivity, and lethality.2,3 Likewise, defects in cytoplasmic tRNA modifications cause human neurological disorders, including familial dysautonomia4−6 and numerous types of intellectual disability (ID), often with accompanying disease phenotypes.7−23 Moreover, genes encoding tRNA modification enzymes or predicted modification enzymes have been linked to other diseases, including many mitochondrial disorders24,25 and cancer.26 Furthermore, modifications have also been shown to play a role in stem cell function,27−29 response to cellular stress,30−32 and host/pathogen interactions,33−36 among others.

One of the most common posttranscriptional tRNA modifications is 2′-O-methylation,1,37 which is found on residues 4, 18, 32, 34, and 44 of certain yeast tRNAs.1 In yeast, 2′-O-methylation of residues 32 (Nm32) and 34 (Nm34) requires the methyltransferase Trm7.38 Lack of both Cm32 and Gm34 on tRNAPhe in trm7Δ mutants causes slow growth in both S. cerevisiae and Schizosaccharomyces pombe cells.38−40 The exact cause of this defect is not entirely clear. S. cerevisiaetrm7Δ mutants grown in minimal media have a charging defect, but this defect is not observed in S. cerevisiaetrm7Δ mutants grown in rich media nor in S. pombetrm7Δ mutants.41 In trm7Δ mutants from both yeast species, the general amino acid control (GAAC) pathway is constitutively active,41 suggesting that lack of Nm32 and Nm34 leads to translational stalling and ribosome collisions.42,43 Lack of these modifications also results in loss of wybutosine (yW) formation at the 1-methylguanosine residue found at position 37 (m1G37) on tRNAPhe.38−40

In humans, defects in Nm32 and Nm34 caused by mutation of the human TRM7 ortholog FTSJ1 cause non-syndromic X-linked ID (NSXLID).14,16 Human cell lines lacking FTSJ1 exhibit a growth defect that is exacerbated in the presence of the translation inhibitor paromomycin,41 and are more sensitive to vaccinia virus infection.34,45 Mice lacking FTSJ1 show impaired learning, anxiety-like behavior, increased sensitivity to pain, metabolic differences, and other phenotypes.46,47 The identity of the hypomodified tRNA(s) that causes these phenotypes in humans and mice lacking FTSJ1 is likely tRNAPhe because loss of FTSJ1 causes a reduction in steady-state levels of tRNAPhe in the brains of mice47 and because decoding of Phe codons, and in particular UUU, is perturbed in both mice and in cultured human cells.44,47 Interestingly, in Drosophila melanogaster, there are two Trm7/FTSJ1 paralogs, one of which modifies position 32 on substrate tRNAs and the other modifies position 34 on substrates. Flies lacking these tRNA modification genes showed a decreased size and lifespan and a decrease in defense against the Drosophila C virus, and their tRNAPhe lacking Gm34 was susceptible to fragmentation after heat shock.48

In the yeasts S. cerevisiae and S. pombe, Trm7 forms a complex with the protein Trm732 to form Cm32 and a complex with the protein Trm734 to form Nm34 on tRNA (Figure 1).39,40 These partner proteins are required for Trm7 activity because lack of Trm732 causes complete loss of Nm32, and lack of Trm734 causes complete loss of Nm34.39,40 Trm7 forms distinct complexes with each protein, suggesting that the role of each is to direct Trm7 to a given nucleotide target.40,49 Trm732 is an armadillo repeat protein which contains a DUF2428 domain (domain of unknown function),40 whereas Trm734 is a WD40 protein.49,50

Figure 1.

Figure 1

Open in a new tab

Schematic of 2′-O-methylation of the anticodon loop of tRNAPhe in yeast. In yeast, the Trm7–Trm732 complex forms Cm32 on tRNAPhe, and the Trm7–Trm734 complex forms Gm34.

In humans and other multicellular eukaryotes, Trm732 and Trm734 orthologs are also involved in 2′-O-methylation of the anticodon loop by the Trm7 ortholog FTJS1. The predicted human ortholog of Trm732 is THADA (thyroid adenoma-associated protein), and overexpression of human THADA in yeast complements the lack of Trm732 by allowing the formation of Cm32 on tRNAPhe.39 However, the requirement of THADA for Nm32 formation in human cells has not been established. Likewise, D. melanogaster has a Trm732/THADA homolog,48 but the role of this protein in Cm32 modification has not been determined. The Trm734 homolog in humans is WDR6, which forms a complex with FTSJ1 and is required with FTSJ1 to form Gm34 on tRNAPhe both in cells and in vitro.44,47 Although the precise roles of Trm732 and Trm734 in tRNA methylation are not known, the analysis of the recently solved crystal structure of the yeast Trm7–Trm734 complex suggests that Trm734 is required to correctly position the substrate tRNA onto the Trm7–Trm734 enzyme.49 Moreover, human WDR6 by itself and the FTSJ1–WDR6 complex bind tRNA, whereas FTSJ1 alone does not, further indicating that WDR6 functions in tRNA binding.44

THADA and WDR6 are also implicated in several biological processes not obviously related to tRNA modification. THADA was first identified as being associated with thyroid adenomas51 and has been shown to be involved in thermogenesis in D. melanogaster,52 and in cold resistance in the model plant Arabidopsis thaliana.53 A recent report also proposed a role for THADA as a regulator of programmed death-ligand 1 (PD-L1) maturation.54 A genome wide association study (GWAS) also suggested that THADA plays a role in cold adaptation in humans.55 Other GWAS analyses have implicated single nucleotide polymorphisms (SNPs) of THADA in polycystic ovary syndrome (PCOS),56 prostate cancer,57,58 and type 2 diabetes.59−62 Although WDR6 has not been implicated in human diseases, it was recently identified with FTSJ1 as a host range restriction factor for a mutant vaccinia virus,34,45 suggesting a possible role for WDR6 in host defense. Because none of these studies involving THADA or WDR6 in higher eukaryotes has included a tRNA modification analysis, it is not clear whether these additional biological roles are due to tRNA modification activity or other bona fide functions of the proteins.

To further understand the role of Trm732 in the Trm7 methyltransferase reaction, we sought to identify regions of this protein important for 2′-O-methylation of tRNA in yeast. We report the identification of an important motif in Trm732 that is required for tRNA modification activity. This motif is also required for the activity of human THADA. Our identification of residues required for Trm732/THADA activity should allow for experiments to determine whether the roles of this protein in diverse biological processes are dependent on tRNA modification activity or on other functions of the protein.

Results

A Conserved Motif in the DUF2428 Domain of Trm732 is Required for Cm32 Modification on tRNAPhe

To study the role of Trm732 in formation of the Cm32 modification, we sought to identify amino acid residues important for Trm732 function. Trm732 proteins are large and consist of armadillo repeats (Figure 2A), with the S. cerevisiae protein containing 1420 amino acids, including 312 amino acids comprising the DUF2428 domain. There is little detectable sequence homology among Trm732 proteins, except for the DUF2428 domain and small regions near the C-terminus. Even the DUF2428 domain, which has the highest amount of conservation, is only around 30% identical between the human and S. cerevisiae proteins.39 To identify regions of conservation among Trm732 proteins that may be required for tRNA modification activity, we performed an amino acid alignment with S. cerevisiae and S. pombe Trm732, human THADA, and five other putative Trm732 proteins from divergent eukaryotic species. We identified three motifs of conserved amino acids. The largest stretch of amino acid similarity was found in motif 2, comprising residues 748–754 in the DUF2428 domain of S. cerevisiae Trm732 with a strong consensus sequence of RRSAGLP (Figure 2A).

Figure 2.

Figure 2

Open in a new tab

Motif 2 of Trm732 is required for Cm32 formation on tRNAPhe. (A) Schematic representation of the Trm732 sequence. Inset box is an amino acid alignment of regions of high sequence similarity between Trm732 proteins from eight eukaryotes. Arrows point to the amino acids changed in Trm732 variants tested in this study. (B) Several conserved amino acids in Trm732 are required for suppression of the slow growth of trm732Δ trm734Δ mutants. Indicated strains containing URA3 and LEU2 plasmids were grown overnight in SD – Leu medium, diluted to an OD600 of ∼0.5, serially diluted 10-fold, and then spotted on medium containing 5-FOA to select against the URA3 plasmid. Cells were grown for 2 days at 30 °C. (C) Conserved amino acids in Trm732 are required for Cm32 formation on tRNAPhe in yeast. Quantification of nucleosides by UPLC from tRNAPhe purified from indicated yeast strains, (*) levels below the threshold of detection.

To test the requirement of these motifs for Trm732 function, we generated variants that replaced conserved amino acids with alanine residues, expressed them in yeast from a low-copy CEN plasmid, and tested their ability to form Cm32 on tRNAPhe. First, we tested whether Trm732 variants with amino acid changes in each motif could rescue the slow growth of trm732Δ trm734Δ double-mutant cells. We used the trm732Δ trm734Δ double mutant because trm732Δ single mutants do not have an obvious growth phenotype.40 Expression of functional Trm732 proteins in the double-mutant strain should lead to normal levels of Cm32 on tRNAPhe, resulting in a tRNAPhe anticodon loop modification profile identical to the healthy growing trm734Δ strain.40 We therefore transformed plasmids expressing Trm732 variants into a trm732Δ trm734Δ [TRM734 URA3] strain and then tested growth after plating on media containing 5-fluoroorotic acid (5-FOA) to select against the [TRM734 URA3] plasmid. trm732Δ trm734Δ mutant cells expressing wild-type Trm732 were healthy, as were the cells expressing the motif 1 variant Trm732-RH702AA and the motif 3 variant Trm732-HG976AA (Figure 2B). In contrast, trm732Δ trm734Δ mutants expressing the motif 2 variants Trm732-RRS750AAA or Trm732-GLP754AAA grew only slightly better than mutants expressing a vector, indicating that motif 2 is important for Trm732 activity. Mutants expressing the Trm732-RRS750AAA-GLP754AAA double variant grew as poorly as cells expressing only a vector (Figure 2B), further demonstrating the importance of motif 2 for modification activity. To verify that the TRM732 genes were transcribed, we performed quantitative real-time PCR (qRT-PCR) and found that mRNA was expressed for each gene construct (Table 1). Thus, loss of complementation is likely due to loss of Trm732 function, although we note the possibility that it could be due to loss of protein stability.

Table 1. Relative mRNA Levels of Mutant TRM732 Genes.

strain plasmid relative levela
wild type vec 1.00 ± 0.14
trm732Δ trm734Δ vec 0.096 ± 0.03
trm732Δ trm734Δ TRM732 3.75 ± 0.57
trm732Δ trm734Δ TRM732-RRS750AAA 3.12 ± 0.16
trm732Δ trm734Δ TRM732-GLP754AAA 2.94 ± 0.28
trm732Δ trm734Δ TRM732-HG976AA 3.25 ± 0.82
trm732Δ trm734Δ TRM732-RH702AA 3.86 ± 0.43
trm732Δ trm734Δ TRM732-RRS750AAA, GLP754AAA 3.70 ± 0.58
trm732Δ trm734Δ TRM732-R748A 4.44 ± 0.68
trm732Δ trm734Δ TRM732-S750A 2.88 ± 0.08
trm732Δ trm734Δ TRM732-G752A 2.47 ± 0.29
trm732Δ trm734Δ TRM732-L753A 2.91 ± 0.09
trm732Δ trm734Δ TRM732-P754A 4.18 ± 2.43
Open in a new tab
a

Relative to TRM732 in wild-type cells after normalization to ACT1. Values are from three independent growths.

To determine if the inability of Trm732 motif 2 variants to rescue the slow growth of the trm732Δ trm734Δ strain was due to loss of Cm32 activity, we purified tRNAPhe from a trm732Δ single mutant expressing Trm732 variants and analyzed the nucleoside content by ultra-pressure liquid chromatography (UPLC). As expected, tRNAPhe from trm732Δ strains expressing wild-type Trm732 had levels of Cm similar to those from a wild-type strain, whereas trm732Δ strains without a Trm732 expression plasmid had no detectable Cm (Figure 2C). We found that tRNAPhe from trm732Δ strains expressing the motif 2 variants Trm732-RRS750AAA and Trm732-GLP754AAA had severely reduced levels of Cm, and strains expressing the motif 2 double-variant Trm732-RRS750AAA-GLP754AAA had even less Cm. In contrast, tRNAPhe from trm732Δ strains expressing motif 1 or motif 3 variants had relatively high levels of Cm, nearly as high as those found on tRNAPhe from trm732Δ strains expressing wild-type Trm732 (Figure 2C).

As expected, because we did these experiments in trm732Δ single mutants, which express Trm734, levels of Gm on tRNAPhe from these strains were similar to those from tRNAPhe from a wild-type strain regardless of the Trm732 plasmid expressed. Small, but detectable, levels of m1G were observed on tRNAPhe from trm732Δ strains expressing an empty vector or expressing Trm732 motif 2 variants (Figure 2C). The presence of m1G on tRNAPhe in certain mutants is most likely due to a defect in yW37 formation because m1G37 is the precursor to yW37, and trm732Δ mutants have been shown previously to have a defect in yW levels.40 Thus, the defects in Cm32 formation in mutants expressing Trm732 variants cause decreased yW37 formation, resulting in detection of m1G. Levels of 2-methylguanosine (m2G) on tRNAPhe from each strain were similar, as expected for a control modification that is not formed or influenced by Trm7 (Figure 2C). Overall, these results demonstrate that for the Trm732 variants tested, a lack of Cm levels on tRNAPhe corresponded with an inability to rescue the slow growth of a trm732Δ trm734Δ strain and that motif 2 is required for Trm732 tRNA modification activity.

To further determine which individual residues of motif 2 are most important for Trm732 tRNA modification activity, we generated 5 of 6 possible single amino acid variants and tested their ability to rescue the slow growth of the trm732Δ trm734Δ strain. We found that expression of four of these single mutant variants tested suppressed the growth defect of the trm732Δ trm734Δ strain, with the Trm732-R748A variant showing a significant, reproducible suppression defect, especially at 25 °C (Figure 3). Indeed, trm732Δ trm734Δ mutants expressing the Trm732-R748A variant had a generation time of 289 min compared to 210 min for mutants expressing wild-type Trm32, when grown at 25 °C in minimal media (Table 2). The inability of the Trm732-R748A variant to fully suppress the growth defect is almost certainly due to an intermediate level of Cm32 on tRNAPhe. Thus, it is likely that it is the combination of all three amino acid changes in each of the motif 2 variants that causes the bulk of loss of tRNA modification activity.

Figure 3.

Figure 3

Open in a new tab

Requirement of individual motif 2 residues for Trm732 function. (A) Amino acid residue R748 is important for Trm732 function. Strains with plasmids as indicated were grown overnight in SD-Leu and analyzed as in Figure 2B, after incubation for 2 days at 30 °C. In the top panel, following growth on 5-FOA at 30 °C, cells were spotted on YPD at 25 °C and incubated for 2 days.

Table 2. Comparison of Generation Times for trm732Δ trm734Δ Mutants Expressing Trm732 Variants in Minimal Media at 25 °C.

straina TRM732 plasmid generation time (min)
wild type vec 206 ± 12
trm732Δ trm734Δ vec 484 ± 19
trm732Δ trm734Δ wild type 210 ± 6
trm732Δ trm734Δ RRS750AAA 444 ± 31
trm732Δ trm734Δ R748A 289 ± 29
trm732Δ trm734Δ S750A 217 ± 7
Open in a new tab
a

Mean and standard deviations based on growth from three separate colonies.

Human THADA Requires Motif 2 for Complementation of the Yeast trm732Δ Mutant

To determine if motif 2 is also required for the activity of Trm732 from another organism, we determined whether the corresponding motif 2 residues are required for Cm formation activity by human THADA. Additionally, to determine the effect of changing the corresponding amino acid residues in human THADA that were not required for yeast Trm732 activity, we also tested a THADA motif 1 variant. We previously showed that expression of human THADA from a high copy plasmid rescues the slow growth of the yeast trm732Δ trm734Δ mutant by forming Cm on tRNAPhe.39 Therefore, we generated variants of full-length isoform A of human THADA on high copy (2μ) expression plasmids under control of the PGAL promoter and tested their ability to rescue the trm732Δ trm734Δ [TRM734 URA3] strain when plated on galactose media with 5-FOA. As expected, we found that wild-type THADA rescued the slow growth of the double mutant (Figure 4). Change of conserved amino acids in motif 2 of THADA severely impaired the ability of the protein to rescue the slow growth of the trm732Δ trm734Δ mutants (THADA-RRS1161AAA and THADA-GIP1165AAA). In contrast to what we observed for the yeast Trm732, expression of human THADA with amino acid changes in motif 1 (THADA-RH1105AA) only partially rescued the slow growth of the trm732Δ trm734Δ mutant (Figure 4). To verify that the THADA genes were expressed, we performed qRT-PCR and found that mRNA was expressed for each gene construct (Table 3). Because THADA expression has previously been shown to restore Cm32 to tRNAPhe in yeast lacking TRM732,39 these results strongly suggest that failure of THADA variants to restore growth is due to the lack of Cm32 formation on tRNAPhe. Partial rescue by a motif 1 variant may be due to the fact that the analysis of THADA variants in yeast is a more sensitive assay than the analysis of yeast Trm732 variants. We conclude that the importance of motif 2 is conserved in both Trm732/THADA, likely similarly affecting THADA protein function, although we note as above that amino acid changes in THADA could cause loss of protein stability, thereby causing loss of complementation by the variants in yeast.

Figure 4.

Figure 4

Open in a new tab

Human THADA requires motif 2 for complementation of the yeast trm732Δ mutant. Indicated strains were grown overnight in the S medium containing raffinose and galactose; diluted as in Figure 2B; spotted to medium containing raffinose, galactose, and 5-FOA; and then incubated for 3 days at 30 °C.

Table 3. Relative mRNA Levels of Mutant THADA Genes Expressed in Yeast.

strain plasmid relative levela
trm732Δ trm734Δ THADA 34.4 ± 8.8
trm732Δ trm734Δ vec <0.01
trm732Δ trm734Δ THADA-RH1105AA 52.0 ± 11.0
trm732Δ trm734Δ THADA-RRS1161AAA 41.7 ± 4.8
trm732Δ trm734Δ THADA-GIP1165AAA 40.3 ± 1.9
Open in a new tab
a

Relative to S. cerevisiaeTUB1 after normalization of both genes to ACT1. Values are from three independent growths.

Discussion

In this study, we have identified an amino acid motif in yeast Trm732 that is required for Trm7-dependent formation of Cm32 on tRNAPhe and have shown that this same motif is required for the activity of the human Trm732 ortholog THADA. Substitution of the RRSAGLP754 residues of motif 2 of yeast Trm732 with alanine residues resulted in a nearly complete lack of Cm modification on tRNAPhe (Figure 2) and a growth defect similar to a vector control in trm732Δ trm734Δ strains expressing the variant (Figure 2). Replacing either RRS750 or GLP754 residues in this motif with alanine residues also resulted in a significant loss of modification activity (Figure 2), indicating that both of these stretches of amino acids are important for modification activity. Our finding that Trm732 variants with individual amino acid substitutions complemented, or mostly complemented, the growth defect of the trm732Δ trm734Δ mutant (Figure 3) suggests that none of the residues we tested are directly involved in catalysis but rather involved in other functions such as protein/tRNA interaction or are required for protein/protein interactions.

Motif 2 is highly conserved in Trm732 proteins throughout eukaryotes (Figure 2), and changes in residues of this motif in THADA also resulted in loss of activity (Figure 4). Because the structure of the Trm7–Trm732 complex has not been solved, the role of Trm732 motif 2 amino acid residues for the formation of Cm32 is not clear. One possible role for motif 2 residues could be tRNA binding and/or proper positioning of the tRNA in the active site to ensure that residue 32 is modified, with the arginine residues possibly interacting directly with the tRNA, and other residues involved in important hairpin turns common to armadillo proteins, which are known to be involved in RNA binding.63 Another plausible explanation for loss of activity in motif 2 variants is that these amino acids are critical for protein–protein interactions between Trm732 and Trm7. Additional biochemical experiments could help determine the role(s) these residues play in tRNA modification.

Our results also shed some light on the levels of 2′-O-methylation in the anticodon loop required for proper growth in yeast. Somewhat surprisingly, we found that low levels of Cm32 on tRNAPhe led to detectable rescue of slow growth. For instance, tRNAPhe from trm732Δ mutants expressing the Trm732 RRS750 and GLP754 variants had levels of Cm32 approximately 10% of that from trm732Δ mutants expressing wild-type Trm732 (Figure 2), but trm732Δ cells expressing these variants still showed a detectable improvement in growth over cells expressing an empty vector (Figure 2). The role of Nm32 on tRNA is not known, but our results suggest that it has an important role in S. cerevisiae because low levels of this modification fix some of the growth defects of the trm732Δ trm734Δ mutants. We note that Cm32 also likely has a role in S. pombe based on the severe growth defect of S. pombetrm7Δ mutants and the more mild growth defect of S. pombetrm734Δ mutants.

Our results and other recent findings further support the idea that the primary function of Trm732 and Trm734 and their orthologs in other eukaryotes is likely tRNA modification. The role of THADA in Nm32 formation in multicellular eukaryotes has not been established, although the ability of human THADA to complement yeast trm732Δ mutants by interacting with yeast Trm7 strongly suggests that its tRNA modification function will also be conserved.39 Our finding that yeast Trm732 and human THADA variants with a mutated motif 2 lack tRNA activity makes it possible to determine if the thermogenesis phenotype in D. melanogaster THADA mutants52 and the PD-L1 phenotype in human cells54 are due to the lack of tRNA modification activity or uncharacterized protein activity. Likewise, the recent finding that human WDR6 is required for Nm34 activity in human cells,41 that it is required for in vitro activity,47 and that it forms a complex with FTSJ141,44 further shows the conserved and critical role of Trm734/WDR6 proteins in tRNA modification. Further experiments using THADA and WDR6 variants with impaired tRNA modification activity could help clarify the role of these proteins in other biological processes.

Methods

Yeast Strains and Plasmids

Yeast strains are listed in Table 4. All yeast strains were constructed using standard techniques, as described previously.40 Plasmids are listed in Table 5. The CEN LEU2 TRM732 expression plasmid was constructed by ligation-independent cloning (LIC) into pAVA581.64 Plasmids expressing Trm732 and full-length human isoform A THADA variants were generated by QuickChange PCR (Stratagene) or Q5 site-directed mutagenesis (New England Biolabs). All plasmids were confirmed by sequencing prior to use.

Table 4. Strains Used in This Study.

strain genotype source
BY4741 MATa his3-Δ1leu2Δ0 met15-Δ0ura3-Δ0  
yMG814-1 BY4741, trm732Δ::bleR ref 40
yMG818-1 BY4741, trm734Δ::bleR trm732Δ::kanMX [CEN URA3 TRM734] ref 40
Open in a new tab

Table 5. Plasmids Used in This Study.

plasmid parent description source
pBP2A   CEN URA3 TRM734 ref 40
pAVA581   CEN LEU2 LIC ref 64
pMG586 pMG586 CEN LEU2 TRM732 this study
pMG581 pMG586 CEN LEU2TRM732-RRS750AAA this study
pMG582 pMG586 CEN LEU2TRM732-GLP754AAA this study
pMG584 pMG586 CEN LEU2TRM732-HG976AA this study
pMG585 pMG586 CEN LEU2TRM732-RH702AA this study
pMG619A pMG582 CEN LEU2TRM732-RRS750AAA, GLP754AAA this study
pMG739C pMG586 CEN LEU2TRM732-R748A this study
pMG741B pMG586 CEN LEU2TRM732-S750A this study
pMG742E pMG586 CEN LEU2TRM732-G752A this study
pMG743A pMG586 CEN LEU2TRM732-L753A this study
pMG744E pMG586 CEN LEU2TRM732-P754A this study
pMG245A   2μ LEU2 PGALTHADA ref 39
pMG643A pMG245A 2μ LEU2 PGALTHADA-RH1105AA this study
pMG644 pMG245A 2μ LEU2 PGALTHADA-RRS1161AAA this study
pMG645A pMG245A 2μ LEU2 PGALTHADA-GIP1165AAA this study
Open in a new tab

Isolation of RNA from Yeast Cells

S. cerevisiaetrm732Δ strains harboring CEN plasmids expressing Trm732 variants were grown in liquid dropout media to an OD of ∼2. RNA was extracted using the hot phenol method.65

Quantitative Real-Time PCR

RNA was treated with RQ1 RNase-free DNase (Promega), followed by reverse transcription using a Verso cDNA Kit (Thermo Scientific) with a 3:1 (v/v) mix of random hexamers and anchored oligo-dT primers. After reverse transcription, DNA was PCR-amplified using DyNAmo HS SYBR Green qPCR Kit (Thermo Scientific) master mix using primers specific to indicated genes. RNA levels were normalized to ACT1.

Purification of tRNA and Analysis of Modified Nucleosides by UPLC

Specific tRNA was purified using complementary biotinylated oligos, followed by digestion of tRNA to nucleosides using P1 nuclease and phosphatase as previously described.65 After purification, tRNA from yeast was analyzed by UPLC using a 50 mm HSS T3 C18 column with a 1.8 μm particle size. The buffer system consisted of buffer A (5 mM NaOAc pH 7.1 + 0.1% Acetonitrile) and buffer B (60% ACN). At a flow rate of 0.46 mL/min, the gradient was as follows: 98% buffer A for 8.92 min; a gradient to achieve 10% buffer B at 15.45 min; and a gradient to achieve 25% buffer B at 29.73 min, followed by 100% buffer B for 2 min..

Acknowledgments

We thank members of the Guy and Phizicky laboratories for helpful discussions and support. D.J.D and H.A.S. were partially supported by Greaves scholarships, and H.M.F. was partially supported by the NIGMS grant 8P20GM103436-14 to the Kentucky IDeA Networks of Biomedical Research Excellence (KY INBRE). This work was supported by the NIGMS grant 8P20GM103436-14 to KY INBRE, and by NIH grants 1R15GM128050 to M.P.G. and GM052347 to E.M.P.

Author Present Address

§ Department of Biological Chemistry and Pharmacology, The Ohio State University, 173 Rightmire Hall, 1060 Carmack Road, Columbus, OH 43201, United States

Author Present Address

∥ School of Medicine, University of Louisville, 500 South Preston Street, Louisville, KY 40202, United States

Author Present Address

⊥ College of Medicine—Northern Kentucky Campus, University of Kentucky, Highland Heights Campus, 100 Grant Drive, Highland Heights, KY 41076, United States

Author Present Address

# Department of Genetics, Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA 02115, United States

Author Present Address

∇ Wood Hudson Cancer Research Laboratory, 931 Isabella Street, Newport, KY 41071, United States

The authors declare no competing financial interest.

References

  1. Boccaletto P.; Machnicka M. A.; Purta E.; Piątkowski P.; Bagiński B.; Wirecki T. K.; de Crécy-Lagard V.; Ross R.; Limbach P. A.; Kotter A.; Helm M.; Bujnicki J. M. MODOMICS: A Database of RNA Modification Pathways. 2017 Update. Nucleic Acids Res. 2018, 46, D303–D307. 10.1093/nar/gkx1030. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Hopper A. K. Transfer RNA Post-Transcriptional Processing, Turnover, and Subcellular Dynamics in the Yeast Saccharomyces Cerevisiae. Genetics 2013, 194, 43–67. 10.1534/genetics.112.147470. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Phizicky E. M.; Hopper A. K. TRNA Biology Charges to the Front. Genes Dev. 2010, 24, 1832–1860. 10.1101/gad.1956510. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Anderson S. L.; Coli R.; Daly I. W.; Kichula E. A.; Rork M. J.; Volpi S. A.; Ekstein J.; Rubin B. Y. Familial Dysautonomia Is Caused by Mutations of the IKAP Gene. Am. J. Hum. Genet. 2001, 68, 753–758. 10.1086/318808. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cuajungco M. P.; Leyne M.; Mull J.; Gill S. P.; Lu W.; Zagzag D.; Axelrod F. B.; Maayan C.; Gusella J. F.; Slaugenhaupt S. A. Tissue-Specific Reduction in Splicing Efficiency of IKBKAP Due to the Major Mutation Associated with Familial Dysautonomia. Am. J. Hum. Genet. 2003, 72, 749–758. 10.1086/368263. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Karlsborn T.; Tükenmez H.; Chen C.; Byström A. S. Familial Dysautonomia (FD) Patients Have Reduced Levels of the Modified Wobble Nucleoside Mcm5s2U in TRNA. Biochem. Biophys. Res. Commun. 2014, 454, 441–445. 10.1016/j.bbrc.2014.10.116. [DOI] [PubMed] [Google Scholar]
  7. Abbasi-Moheb L.; Mertel S.; Gonsior M.; Nouri-Vahid L.; Kahrizi K.; Cirak S.; Wieczorek D.; Motazacker M. M.; Esmaeeli-Nieh S.; Cremer K.; Weißmann R.; Tzschach A.; Garshasbi M.; Abedini S. S.; Najmabadi H.; Ropers H. H.; Sigrist S. J.; Kuss A. W. Mutations in NSUN2 Cause Autosomal-Recessive Intellectual Disability. Am. J. Hum. Genet. 2012, 90, 847–855. 10.1016/j.ajhg.2012.03.021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Alazami A. M.; Hijazi H.; Al-Dosari M. S.; Shaheen R.; Hashem A.; Aldahmesh M. A.; Mohamed J. Y.; Kentab A.; Salih M. A.; Awaji A.; Masoodi T. A.; Alkuraya F. S. Mutation in ADAT3, Encoding Adenosine Deaminase Acting on Transfer RNA, Causes Intellectual Disability and Strabismus. J. Med. Genet. 2013, 50, 425–430. 10.1136/jmedgenet-2012-101378. [DOI] [PubMed] [Google Scholar]
  9. Arrondel C.; Missoury S.; Snoek R.; Patat J.; Menara G.; Collinet B.; Liger D.; Durand D.; Gribouval O.; Boyer O.; Buscara L.; Martin G.; Machuca E.; Nevo F.; Lescop E.; Braun D. A.; Boschat A.-C.; Sanquer S.; Guerrera I. C.; Revy P.; Parisot M.; Masson C.; Boddaert N.; Charbit M.; Decramer S.; Novo R.; Macher M.-A.; Ranchin B.; Bacchetta J.; Laurent A.; Collardeau-Frachon S.; van Eerde A. M.; Hildebrandt F.; Magen D.; Antignac C.; van Tilbeurgh H.; Mollet G. Defects in T6A TRNA Modification Due to GON7 and YRDC Mutations Lead to Galloway-Mowat Syndrome. Nat. Commun. 2019, 10, 3967. 10.1038/s41467-019-11951-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. de Brouwer A. P. M.; Abou Jamra R.; Körtel N.; Soyris C.; Polla D. L.; Safra M.; Zisso A.; Powell C. A.; Rebelo-Guiomar P.; Dinges N.; Morin V.; Stock M.; Hussain M.; Shahzad M.; Riazuddin S.; Ahmed Z. M.; Pfundt R.; Schwarz F.; de Boer L.; Reis A.; Grozeva D.; Raymond F. L.; Riazuddin S.; Koolen D. A.; Minczuk M.; Roignant J.-Y.; van Bokhoven H.; Schwartz S. Variants in PUS7 Cause Intellectual Disability with Speech Delay, Microcephaly, Short Stature, and Aggressive Behavior. Am. J. Hum. Genet. 2018, 103, 1045–1052. 10.1016/j.ajhg.2018.10.026. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Cohen J. S.; Srivastava S.; Farwell K. D.; Lu H.-M.; Zeng W.; Lu H.; Chao E. C.; Fatemi A. ELP2 Is a Novel Gene Implicated in Neurodevelopmental Disabilities. Am. J. Med. Genet., Part A 2015, 167, 1391–1395. 10.1002/ajmg.a.36935. [DOI] [PubMed] [Google Scholar]
  12. Edvardson S.; Prunetti L.; Arraf A.; Haas D.; Bacusmo J. M.; Hu J. F.; Ta-Shma A.; Dedon P. C.; de Crécy-Lagard V.; Elpeleg O. TRNA N6-Adenosine Threonylcarbamoyltransferase Defect Due to KAE1/TCS3 (OSGEP) Mutation Manifest by Neurodegeneration and Renal Tubulopathy. Eur. J. Hum. Genet. 2017, 25, 545–551. 10.1038/ejhg.2017.30. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Fahiminiya S.; Almuriekhi M.; Nawaz Z.; Staffa A.; Lepage P.; Ali R.; Hashim L.; Schwartzentruber J.; Abu Khadija K.; Zaineddin S.; Gamal H.; Majewski J.; Ben-Omran T. Whole Exome Sequencing Unravels Disease-Causing Genes in Consanguineous Families in Qatar. Clin. Genet. 2014, 86, 134–141. 10.1111/cge.12280. [DOI] [PubMed] [Google Scholar]
  14. Freude K.; Hoffmann K.; Jensen L.-R.; Delatycki M. B.; des Portes V.; Moser B.; Hamel B.; van Bokhoven H.; Moraine C.; Fryns J.-P.; Chelly J.; Gécz J.; Lenzner S.; Kalscheuer V. M.; Ropers H.-H. Mutations in the FTSJ1 Gene Coding for a Novel S-Adenosylmethionine-Binding Protein Cause Nonsyndromic X-Linked Mental Retardation. Am. J. Hum. Genet. 2004, 75, 305–309. 10.1086/422507. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Gillis D.; Krishnamohan A.; Yaacov B.; Shaag A.; Jackman J. E.; Elpeleg O. TRMT10A Dysfunction Is Associated with Abnormalities in Glucose Homeostasis, Short Stature and Microcephaly. J. Med. Genet. 2014, 51, 581–586. 10.1136/jmedgenet-2014-102282. [DOI] [PubMed] [Google Scholar]
  16. Guy M. P.; Shaw M.; Weiner C. L.; Hobson L.; Stark Z.; Rose K.; Kalscheuer V. M.; Gecz J.; Phizicky E. M. Defects in TRNA Anticodon Loop 2′-O-Methylation Are Implicated in Nonsyndromic X-Linked Intellectual Disability Due to Mutations in FTSJ1. Hum. Mutat. 2015, 36, 1176–1187. 10.1002/humu.22897. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Igoillo-Esteve M.; Genin A.; Lambert N.; Désir J.; Pirson I.; Abdulkarim B.; Simonis N.; Drielsma A.; Marselli L.; Marchetti P.; Vanderhaeghen P.; Eizirik D. L.; Wuyts W.; Julier C.; Chakera A. J.; Ellard S.; Hattersley A. T.; Abramowicz M.; Cnop M. TRNA Methyltransferase Homolog Gene TRMT10A Mutation in Young Onset Diabetes and Primary Microcephaly in Humans. PLoS Genet. 2013, 9, e1003888 10.1371/journal.pgen.1003888. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Khan M. A.; Rafiq M. A.; Noor A.; Hussain S.; Flores J. V.; Rupp V.; Vincent A. K.; Malli R.; Ali G.; Khan F. S.; Ishak G. E.; Doherty D.; Weksberg R.; Ayub M.; Windpassinger C.; Ibrahim S.; Frye M.; Ansar M.; Vincent J. B. Mutation in NSUN2, Which Encodes an RNA Methyltransferase, Causes Autosomal-Recessive Intellectual Disability. Am. J. Hum. Genet. 2012, 90, 856–863. 10.1016/j.ajhg.2012.03.023. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Martinez F. J.; Lee J. H.; Lee J. E.; Blanco S.; Nickerson E.; Gabriel S.; Frye M.; Al-Gazali L.; Gleeson J. G. Whole Exome Sequencing Identifies a Splicing Mutation in NSUN2 as a Cause of a Dubowitz-like Syndrome. J. Med. Genet. 2012, 49, 380–385. 10.1136/jmedgenet-2011-100686. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Najmabadi H.; Hu H.; Garshasbi M.; Zemojtel T.; Abedini S. S.; Chen W.; Hosseini M.; Behjati F.; Haas S.; Jamali P.; Zecha A.; Mohseni M.; Püttmann L.; Vahid L. N.; Jensen C.; Moheb L. A.; Bienek M.; Larti F.; Mueller I.; Weissmann R.; Darvish H.; Wrogemann K.; Hadavi V.; Lipkowitz B.; Esmaeeli-Nieh S.; Wieczorek D.; Kariminejad R.; Firouzabadi S. G.; Cohen M.; Fattahi Z.; Rost I.; Mojahedi F.; Hertzberg C.; Dehghan A.; Rajab A.; Banavandi M. J. S.; Hoffer J.; Falah M.; Musante L.; Kalscheuer V.; Ullmann R.; Kuss A. W.; Tzschach A.; Kahrizi K.; Ropers H. H. Deep Sequencing Reveals 50 Novel Genes for Recessive Cognitive Disorders. Nature 2011, 478, 57–63. 10.1038/nature10423. [DOI] [PubMed] [Google Scholar]
  21. Shaheen R.; Abdel-Salam G. M. H.; Guy M. P.; Alomar R.; Abdel-Hamid M. S.; Afifi H. H.; Ismail S. I.; Emam B. A.; Phizicky E. M.; Alkuraya F. S. Mutation in WDR4 Impairs TRNA m7G46 Methylation and Causes a Distinct Form of Microcephalic Primordial Dwarfism. Genome Biol. 2015, 16, 210. 10.1186/s13059-015-0779-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Shaheen R.; Han L.; Faqeih E.; Ewida N.; Alobeid E.; Phizicky E. M.; Alkuraya F. S. A Homozygous Truncating Mutation in PUS3 Expands the Role of TRNA Modification in Normal Cognition. Hum. Genet. 2016, 135, 707–713. 10.1007/s00439-016-1665-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Shaheen R.; Mark P.; Prevost C. T.; AlKindi A.; Alhag A.; Estwani F.; Al-Sheddi T.; Alobeid E.; Alenazi M. M.; Ewida N.; Ibrahim N.; Hashem M.; Abdulwahab F.; Bryant E. M.; Spinelli E.; Millichap J.; Barnett S. S.; Kearney H. M.; Accogli A.; Scala M.; Capra V.; Nigro V.; Fu D.; Alkuraya F. S. Biallelic Variants in CTU2 Cause DREAM-PL Syndrome and Impair Thiolation of TRNA Wobble U34. Hum. Mutat. 2019, 40, 2108–2120. 10.1002/humu.23870. [DOI] [PubMed] [Google Scholar]
  24. Tsutomu S.; Asuteka N.; Takeo S. Human Mitochondrial Diseases Caused by Lack of Taurine Modification in Mitochondrial TRNAs. Wiley Interdiscip. Rev.: RNA 2011, 2, 376–386. 10.1002/wrna.65. [DOI] [PubMed] [Google Scholar]
  25. Bohnsack M. T.; Sloan K. E. The Mitochondrial Epitranscriptome: The Roles of RNA Modifications in Mitochondrial Translation and Human Disease. Cell. Mol. Life Sci. 2018, 75, 241–260. 10.1007/s00018-017-2598-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Pereira M.; Francisco S.; Varanda A.; Santos M.; Santos M.; Soares A. Impact of TRNA Modifications and TRNA-Modifying Enzymes on Proteostasis and Human Disease. Int. J. Mol. Sci. 2018, 19, 3738. 10.3390/ijms19123738. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Guzzi N.; Cieśla M.; Ngoc P. C. T.; Lang S.; Arora S.; Dimitriou M.; Pimková K.; Sommarin M. N. E.; Munita R.; Lubas M.; Lim Y.; Okuyama K.; Soneji S.; Karlsson G.; Hansson J.; Jönsson G.; Lund A. H.; Sigvardsson M.; Hellström-Lindberg E.; Hsieh A. C.; Bellodi C. Pseudouridylation of TRNA-Derived Fragments Steers Translational Control in Stem Cells. Cell 2018, 173, 1204–1216. 10.1016/j.cell.2018.03.008. [DOI] [PubMed] [Google Scholar]
  28. Yoo H.; Son D.; Jang Y.-J.; Hong K. Indispensable Role for Mouse ELP3 in Embryonic Stem Cell Maintenance and Early Development. Biochem. Biophys. Res. Commun. 2016, 478, 631–636. 10.1016/j.bbrc.2016.07.120. [DOI] [PubMed] [Google Scholar]
  29. Blanco S.; Bandiera R.; Popis M.; Hussain S.; Lombard P.; Aleksic J.; Sajini A.; Tanna H.; Cortés-Garrido R.; Gkatza N.; Dietmann S.; Frye M. Stem Cell Function and Stress Response Are Controlled by Protein Synthesis. Nature 2016, 534, 335–340. 10.1038/nature18282. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Blanco S.; Dietmann S.; Flores J. V.; Hussain S.; Kutter C.; Humphreys P.; Lukk M.; Lombard P.; Treps L.; Popis M.; Kellner S.; Hölter S. M.; Garrett L.; Wurst W.; Becker L.; Klopstock T.; Fuchs H.; Gailus-Durner V.; Hrabĕ de Angelis M.; Káradóttir R. T.; Helm M.; Ule J.; Gleeson J. G.; Odom D. T.; Frye M. Aberrant Methylation of TRNAs Links Cellular Stress to Neuro-Developmental Disorders. EMBO J. 2014, 33, 2020–2039. 10.15252/embj.201489282. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Chan C. T. Y.; Dyavaiah M.; DeMott M. S.; Taghizadeh K.; Dedon P. C.; Begley T. J. A Quantitative Systems Approach Reveals Dynamic Control of TRNA Modifications during Cellular Stress. PLoS Genet. 2010, 6, e1001247 10.1371/journal.pgen.1001247. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Endres L.; Dedon P. C.; Begley T. J. Codon-Biased Translation Can Be Regulated by Wobble-Base TRNA Modification Systems during Cellular Stress Responses. RNA Biol. 2015, 12, 603–614. 10.1080/15476286.2015.1031947. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Chionh Y. H.; McBee M.; Babu I. R.; Hia F.; Lin W.; Zhao W.; Cao J.; Dziergowska A.; Malkiewicz A.; Begley T. J.; Alonso S.; Dedon P. C. TRNA-Mediated Codon-Biased Translation in Mycobacterial Hypoxic Persistence. Nat. Commun. 2016, 7, 13302. 10.1038/ncomms13302. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Sivan G.; Glushakow-Smith S. G.; Katsafanas G. C.; Americo J. L.; Moss B. Human Host Range Restriction of the Vaccinia Virus C7/K1 Double Deletion Mutant Is Mediated by an Atypical Mode of Translation Inhibition. J. Virol. 2018, 92, e01329 10.1128/JVI.01329-18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Wang Y.; Li D.; Gao J.; Li X.; Zhang R.; Jin X.; Hu Z.; Zheng B.; Persson S.; Chen P. The 2′-O-Methyladenosine Nucleoside Modification Gene OsTRM13 Positively Regulates Salt Stress Tolerance in Rice. J. Exp. Bot. 2017, 68, 1479–1491. 10.1093/jxb/erx061. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Ramírez V.; González B.; López A.; Castelló M. J.; Gil M. J.; Zheng B.; Chen P.; Vera P. A 2′-O-Methyltransferase Responsible for Transfer RNA Anticodon Modification Is Pivotal for Resistance to Pseudomonas Syringae DC3000 in Arabidopsis. Mol. Plant-Microbe Interact. 2018, 31, 1323–1336. 10.1094/MPMI-06-18-0148-R. [DOI] [PubMed] [Google Scholar]
  37. Ayadi L.; Galvanin A.; Pichot F.; Marchand V.; Motorin Y. RNA Ribose Methylation (2′-O-Methylation): Occurrence, Biosynthesis and Biological Functions. Biochim. Biophys. Acta, Gene Regul. Mech. 2019, 1862, 253. 10.1016/j.bbagrm.2018.11.009. [DOI] [PubMed] [Google Scholar]
  38. Pintard L.; Lecointe F.; Bujnicki J. M.; Bonnerot C.; Grosjean H.; Lapeyre B. Trm7p Catalyses the Formation of Two 2′-O-Methylriboses in Yeast TRNA Anticodon Loop. EMBO J. 2002, 21, 1811–1820. 10.1093/emboj/21.7.1811. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Guy M. P.; Phizicky E. M. Conservation of an Intricate Circuit for Crucial Modifications of the TRNAPhe Anticodon Loop in Eukaryotes. RNA 2015, 21, 61–74. 10.1261/rna.047639.114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Guy M. P.; Podyma B. M.; Preston M. A.; Shaheen H. H.; Krivos K. L.; Limbach P. A.; Hopper A. K.; Phizicky E. M. Yeast Trm7 Interacts with Distinct Proteins for Critical Modifications of the TRNAPhe Anticodon Loop. RNA 2012, 18, 1921–1933. 10.1261/rna.035287.112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Han L.; Guy M. P.; Kon Y.; Phizicky E. M. Lack of 2′-O-Methylation in the TRNA Anticodon Loop of Two Phylogenetically Distant Yeast Species Activates the General Amino Acid Control Pathway. PLoS Genet. 2018, 14, e1007288 10.1371/journal.pgen.1007288. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Yan L. L.; Zaher H. S. Ribosome Quality Control Antagonizes the Activation of the Integrated Stress Response on Colliding Ribosomes. Mol. Cell 2021, 81, 614–628. 10.1016/j.molcel.2020.11.033. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Meydan S.; Guydosh N. R. Disome and Trisome Profiling Reveal Genome-Wide Targets of Ribosome Quality Control. Mol. Cell 2020, 79, 588–602. 10.1016/j.molcel.2020.06.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Li J.; Wang Y. N.; Xu B. S.; Liu Y. P.; Zhou M.; Long T.; Li H.; Dong H.; Nie Y.; Chen P. R.; Wang E. D.; Liu R. J. Intellectual Disability-Associated Gene Ftsj1 Is Responsible for 2′-O-Methylation of Specific TRNAs. EMBO Rep. 2020, 21, e50095 10.15252/embr.202050095. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Sivan G.; Ormanoglu P.; Buehler E. C.; Martin S. E.; Moss B. Identification of Restriction Factors by Human Genome-Wide RNA Interference Screening of Viral Host Range Mutants Exemplified by Discovery of SAMD9 and WDR6 as Inhibitors of the Vaccinia Virus K1L-C7L- Mutant. mBio 2015, 6, e01122 10.1128/mBio.01122-15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Jensen L. R.; Garrett L.; Hölter S. M.; Rathkolb B.; Rácz I.; Adler T.; Prehn C.; Hans W.; Rozman J.; Becker L.; Aguilar-Pimentel J. A.; Puk O.; Moreth K.; Dopatka M.; Walther D. J.; von Bohlen Und Halbach V.; Rath M.; Delatycki M.; Bert B.; Fink H.; Blümlein K.; Ralser M.; Van Dijck A.; Kooy F.; Stark Z.; Müller S.; Scherthan H.; Gecz J.; Wurst W.; Wolf E.; Zimmer A.; Klingenspor M.; Graw J.; Klopstock T.; Busch D.; Adamski J.; Fuchs H.; Gailus-Durner V.; de Angelis M. H.; Ropers H.-H.; Kuss A. W.; Kuss A. W. A Mouse Model for Intellectual Disability Caused by Mutations in the X-Linked 2′-O-methyltransferase Ftsj1 Gene. Biochim. Biophys. Acta, Mol. Basis Dis. 2019, 1865, 2083–2093. 10.1016/j.bbadis.2018.12.011. [DOI] [PubMed] [Google Scholar]
  47. Nagayoshi Y.; Chujo T.; Hirata S.; Nakatsuka H.; Chen C.-W.; Takakura M.; Miyauchi K.; Ikeuchi Y.; Carlyle B. C.; Kitchen R. R.; Suzuki T.; Katsuoka F.; Yamamoto M.; Goto Y.; Tanaka M.; Natsume K.; Nairn A. C.; Suzuki T.; Tomizawa K.; Wei F.-Y. Loss of Ftsj1 Perturbs Codon-Specific Translation Efficiency in the Brain and Is Associated with X-Linked Intellectual Disability. Sci. Adv. 2021, 7, eabf3072 10.1126/sciadv.abf3072. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Angelova M. T.; Dimitrova D. G.; Da Silva B.; Marchand V.; Jacquier C.; Achour C.; Brazane M.; Goyenvalle C.; Bourguignon-Igel V.; Shehzada S.; Khouider S.; Lence T.; Guerineau V.; Roignant J.-Y.; Antoniewski C.; Teysset L.; Bregeon D.; Motorin Y.; Schaefer M. R.; Carré C. TRNA 2′-O-Methylation by a Duo of TRM7/FTSJ1 Proteins Modulates Small RNA Silencing in Drosophila. Nucleic Acids Res. 2020, 48, 2050–2072. 10.1093/nar/gkaa002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Hirata A.; Okada K.; Yoshii K.; Shiraishi H.; Saijo S.; Yonezawa K.; Shimizu N.; Hori H. Structure of TRNA Methyltransferase Complex of Trm7 and Trm734 Reveals a Novel Binding Interface for TRNA Recognition. Nucleic Acids Res. 2019, 47, 10942–10955. 10.1093/nar/gkz856. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Shi Y.; Stefan C. J.; Rue S. M.; Teis D.; Emr S. D. Two Novel WD40 Domain-Containing Proteins, Ere1 and Ere2, Function in the Retromer-Mediated Endosomal Recycling Pathway. Mol. Biol. Cell 2011, 22, 4093–4107. 10.1091/mbc.E11-05-0440. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Rippe V.; Drieschner N.; Meiboom M.; Escobar H. M.; Bonk U.; Belge G.; Bullerdiek J. Identification of a Gene Rearranged by 2p21 Aberrations in Thyroid Adenomas. Oncogene 2003, 22, 6111–6114. 10.1038/sj.onc.1206867. [DOI] [PubMed] [Google Scholar]
  52. Moraru A.; Cakan-Akdogan G.; Strassburger K.; Males M.; Mueller S.; Jabs M.; Muelleder M.; Frejno M.; Braeckman B. P.; Ralser M.; Teleman A. A. THADA Regulates the Organismal Balance between Energy Storage and Heat Production. Dev. Cell 2017, 41, 72–81. 10.1016/j.devcel.2017.03.016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Dong Y.; Teleman A. A.; Jedmowski C.; Wirtz M.; Hell R. The Arabidopsis THADA Homologue Modulates TOR Activity and Cold Acclimation. Plant Biol. 2019, 21, 77–83. 10.1111/plb.12893. [DOI] [PubMed] [Google Scholar]
  54. Li C.; Chi H.; Deng S.; Xu K.; Wang H.; Yao H.; Wang Y.; Chen D.; Guo X.; Fang J.-Y.; He F.; Xu J. THADA Drives Golgi Residency and Upregulation of PD-L1 in Cancer Cells and Provides Promising Target for Immunotherapy. J. ImmunoTher. Cancer 2021, 9, e002443 10.1136/jitc-2021-002443. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Cardona A.; Pagani L.; Antao T.; Lawson D. J.; Eichstaedt C. A.; Yngvadottir B.; Shwe M. T. T.; Wee J.; Romero I. G.; Raj S.; Metspalu M.; Villems R.; Willerslev E.; Tyler-Smith C.; Malyarchuk B. A.; Derenko M. V.; Kivisild T. Genome-Wide Analysis of Cold Adaptation in Indigenous Siberian Populations. PLoS One 2014, 9, e98076 10.1371/journal.pone.0098076. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Hiam D.; Moreno-Asso A.; Teede H. J.; Laven J. S. E.; Stepto N. K.; Moran L. J.; Gibson-Helm M. The Genetics of Polycystic Ovary Syndrome: An Overview of Candidate Gene Systematic Reviews and Genome-Wide Association Studies. J. Clin. Med. 2019, 8, 1606. 10.3390/jcm8101606. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Zhao F.; Xu Y.; Yang K.; Liu M.; Wei D.; Zhang Y.; Shi X.; Yang F.; Wang X.; Liang S.; Zhao C.; Chen X.; Sun L.; Zhu X.; Wang N.; Hui J.; Zhang Y.; Zhu L.; Yang Y.; Tang L.; Wang J.; Yang Z. THADA Gene Polymorphism and Prostate Cancer Risk: A Meta-Analysis. Oncol. Res. Treat. 2014, 37, 106–110. 10.1159/000360206. [DOI] [PubMed] [Google Scholar]
  58. Li X.-H.; Xu Y.; Yang K.; Shi J.-J.; Zhang X.; Yang F.; Yuan H.; Zhu X.; Zhang Y.-H.; Wang J.-Y.; Yang Z. Association of THADA, FOXP4, GPRC6A/RFX6 Genes and 8q24 Risk Alleles with Prostate Cancer in Northern Chinese Men. J. Balkan Union Oncol. 2015, 20, 1223–1228. [PubMed] [Google Scholar]
  59. Zeggini E.; Scott L. J.; Scott L. J.; Saxena R.; Voight B. F.; Marchini J. L.; Hu T.; de Bakker P. I.; Abecasis G. R.; Almgren P.; Andersen G.; Ardlie K.; Boström K. B.; Bergman R. N.; Bonnycastle L. L.; Borch-Johnsen K.; Burtt N. P.; Chen H.; Chines P. S.; Daly M. J.; Deodhar P.; Ding C.-J.; Doney A. S. F.; Duren W. L.; Elliott K. S.; Erdos M. R.; Frayling T. M.; Freathy R. M.; Gianniny L.; Grallert H.; Grarup N.; Groves C. J.; Guiducci C.; Hansen T.; Herder C.; Hitman G. A.; Hughes T. E.; Isomaa B.; Jackson A. U.; Jørgensen T.; Kong A.; Kubalanza K.; Kuruvilla F. G.; Kuusisto J.; Langenberg C.; Lango H.; Lauritzen T.; Li Y.; Lindgren C. M.; Lyssenko V.; Marvelle A. F.; Meisinger C.; Midthjell K.; Mohlke K. L.; Morken M. A.; Morris A. D.; Narisu N.; Nilsson P.; Owen K. R.; Palmer C. N.; Payne F.; Perry J. R. B.; Pettersen E.; Platou C.; Prokopenko I.; Qi L.; Qin L.; Rayner N. W.; Rees M.; Roix J. J.; Sandbæk A.; Shields B.; Sjögren M.; Steinthorsdottir V.; Stringham H. M.; Swift A. J.; Thorleifsson G.; Thorsteinsdottir U.; Timpson N. J.; Tuomi T.; Tuomilehto J.; Walker M.; Watanabe R. M.; Weedon M. N.; Willer C. J.; Illig T.; Hveem K.; Hu F. B.; Laakso M.; Stefansson K.; Pedersen O.; Wareham N. J.; Barroso I.; Hattersley A. T.; Collins F. S.; Groop L.; McCarthy M. I.; Boehnke M.; Altshuler D. Meta-Analysis of Genome-Wide Association Data and Large-Scale Replication Identifies Additional Susceptibility Loci for Type 2 Diabetes. Nat. Genet. 2008, 40, 638–645. 10.1038/ng.120. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Bai H.; Liu H.; Suyalatu S.; Guo X.; Chu S.; Chen Y.; Lan T.; Borjigin B.; Orlov Y. L.; Posukh O. L.; Yang X.; Guilan G.; Osipova L. P.; Wu Q.; Narisu N. Association Analysis of Genetic Variants with Type 2 Diabetes in a Mongolian Population in China. J. Diabetes Res. 2015, 2015, 613236. 10.1155/2015/613236. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Cheng I.; Caberto C. P.; Lum-Jones A.; Seifried A.; Wilkens L. R.; Schumacher F. R.; Monroe K. R.; Lim U.; Tiirikainen M.; Kolonel L. N.; Henderson B. E.; Stram D. O.; Haiman C. A.; Le Marchand L. Type 2 Diabetes Risk Variants and Colorectal Cancer Risk: The Multiethnic Cohort and PAGE Studies. Gut 2011, 60, 1703–1711. 10.1136/gut.2011.237727. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. DeMenna J.; Puppala S.; Chittoor G.; Schneider J.; Kim J. Y.; Shaibi G. Q.; Mandarino L. J.; Duggirala R.; Coletta D. K. Association of Common Genetic Variants with Diabetes and Metabolic Syndrome Related Traits in the Arizona Insulin Resistance Registry: A Focus on Mexican American Families in the Southwest. Hum. Hered. 2014, 78, 47–58. 10.1159/000363411. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Rubinson E. H.; Eichman B. F. Nucleic Acid Recognition by Tandem Helical Repeats. Curr. Opin. Struct. Biol. 2012, 22, 101–109. 10.1016/j.sbi.2011.11.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Quartley E.; Alexandrov A.; Mikucki M.; Buckner F. S.; Hol W. G.; DeTitta G. T.; Phizicky E. M.; Grayhack E. J. Heterologous Expression of L. Major Proteins in S. Cerevisiae: A Test of Solubility, Purity, and Gene Recoding. J. Struct. Funct. Genomics 2009, 10, 233–247. 10.1007/s10969-009-9068-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Jackman J. E.; Montange R. K.; Malik H. S.; Phizicky E. M. Identification of the Yeast Gene Encoding the TRNA M1G Methyltransferase Responsible for Modification at Position 9. RNA 2003, 9, 574–585. 10.1261/rna.5070303. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from ACS Omega are provided here courtesy of American Chemical Society

RESOURCES